🇺🇸 FDA
Pipeline program

ACTILYSE, poudre et solvant pour solution injectable et perfusion, ACTILYSE, poudre et solvant pour solution injectable et perfusion, Metalyse 10,000 units powder and solvent for solution for injection, ACTILYSE, poudre et solvant pour solution injectable et perfusion, Metalyse 5 000 units (25 mg) powder for solution for injection

DR230297

Phase 3 small_molecule active

Quick answer

ACTILYSE, poudre et solvant pour solution injectable et perfusion, ACTILYSE, poudre et solvant pour solution injectable et perfusion, Metalyse 10,000 units powder and solvent for solution for injection, ACTILYSE, poudre et solvant pour solution injectable et perfusion, Metalyse 5 000 units (25 mg) powder for solution for injection for Acute ischaemic stroke due to basilar artery occlusion. is a Phase 3 program (small_molecule) at Tour Hekla with 1 ClinicalTrials.gov record(s).

Program details

Company
Tour Hekla
Indication
Acute ischaemic stroke due to basilar artery occlusion.
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials